Physician profile
Roger Altman
NPI 1003898099
$529.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $219 · 2021: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $132.89 | 2019 | |
| Sun Pharmaceutical Industries INC. | $87.39 | 2020-2021 | |
| Leo Pharma INC. | $59.57 | 2020-2021 | |
| Janssen Biotech, INC. | $51.09 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.32 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $37.55 | 2020-2021 | |
| Amgen INC. | $25.98 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.02 | 2020 | |
| Genzyme Corporation | $23.85 | 2021 | |
| Dusa Pharmaceuticals, INC. | $22.75 | 2019 | |
| Dermira, INC. | $13.93 | 2019 | |
| Organogenesis INC. | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.